On Nov. 29, 2021, Thermo Fisher Scientific confirmed that its polymerase chain reaction (PCR) TaqPath COVID-19 Combo Kit and TaqPath COVID-19 CE-IVD RT-PCR Kit, which tested for the presence of SARS-CoV-2, were not impacted by the emerging B.1.1.529, or Omicron variant, enabling accurate test results.